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The signaling of brain-derived neurotrophic factor (BDNF) has been suggested to be
impaired in Alzheimer’s disease (AD), which may compromise the function of BDNF
upon neuronal activity and survival. Accordingly, decreased levels of BDNF and its
tropomyosin-receptor kinase B-full-length (TrkB-FL) have been detected in human brain
samples of AD patients. We have previously found that neuronal exposure to amyloid-β
(Aβ) peptide, a hallmark of AD, leads to calpain overactivation and subsequent TrkB-FL
cleavage leading to decreased levels of TrkB-FL and the generation of two new
fragments: a membrane-bound truncated receptor (TrkB-T′) and an intracellular fragment
(TrkB-ICD). Importantly, we identified this TrkB-FL cleavage and TrkB-ICD presence
in human brain samples, which indicates that this molecular mechanism contributes
to the loss of BDNF signaling in humans. The exact role of this TrkB-ICD fragment
is, however, unknown. Here, we used a human neuroglioma cell line and rat cortical
primary neuronal cultures to track TrkB-ICD intracellularly. Our data show that TrkB-ICD
is a relatively stable fragment that accumulates in the nucleus over time, through a
phosphorylation-dependent process. We also found that TrkB-ICD has tyrosine kinase
activity, inducing the phosphorylation of nuclear and axonal proteins. These findings
suggest that TrkB-ICD may lead to a dysregulation of the activity of several proteins,
including proteins in the nucleus, to where TrkB-ICD migrates. Since TrkB-ICD is
formed by Aβ peptide-induced cleavage of TrkB-FL, the present data highlights a new
mechanism that may have a role in AD pathophysiology.
Keywords: Alzheimer’s disease, brain-derived neurotrophic factor, TrkB-FL cleavage, TrkB-ICD fragment,
excitotoxicity, neuroprotection, neurodegeneration
Abbreviations: Aβ, amyloid-β peptide; BDNF, brain-derived neurotrophic factor; CHX, cycloheximide; MS, mass
spectrometry; NLS, nuclear localization sequence; PKA, protein kinase A; PKC, protein kinase C; PMD, post-mortem delay;
STS, staurosporine; TrkB-FL, full-length isoform of Tropomyosin-receptor kinase B; TrkB-ICD, intracellular domain of
Tropomyosin-receptor kinase B; TrkB-Tc, truncated isoforms of Tropomyosin-receptor kinase B.
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INTRODUCTION
Alzheimer’s disease (AD) is a slow progressing
neurodegenerative disease, leading to atrophy and
neuronal loss of particular brain regions, in particular
the hippocampus, therefore leading to cognitive impairments
(Huang and Mucke, 2012). Together with Tau protein
hyperphosphorylation, amyloid-β (Aβ) peptide has been
considered one of the main players in AD progression
(Huang and Mucke, 2012). It is has been suggested
that brain-derived neurotrophic factor (BDNF) signaling,
one of the major pathways responsible for endogenous
neuroprotection, is dramatically disrupted in AD (Phillips
et al., 1991; Connor et al., 1997; Ferrer et al., 1999;
Arancibia et al., 2008; Zuccato and Cattaneo, 2009; Diniz
and Teixeira, 2011; Kemppainen et al., 2012; Nagahara et al.,
2013; Jerónimo-Santos et al., 2015). BDNF, through the
activation of the full-length isoform of Tropomyosin-receptor
kinase B (TrkB-FL), promotes neuronal growth, survival,
differentiation and synaptic plasticity, thus contributing to
the homeostasis the mammalian nervous system (Huang
and Reichardt, 2001). In addition to TrkB-FL, BDNF can
also activate truncated (Tc) isoforms (TrkB-Tc) that lack
the tyrosine kinase domain, acting as negative modulators
of BDNF signaling (Stoilov et al., 2002). In the brain
of AD patients there is a molecular dysregulation of the
main players of BDNF signaling namely, decreased levels
of BDNF and TrkB-FL and increased levels of TrkB-Tc
(Phillips et al., 1991; Connor et al., 1997; Ferrer et al., 1999;
Kemppainen et al., 2012). In addition, as we recently found
in cell cultures, Aβ peptide, through extrasynaptic NMDA
receptors, promotes the increase of intracellular calcium
levels, leading to the overactivation of calpains, which then
promote TrkB-FL cleavage (Jerónimo-Santos et al., 2015;
Tanqueiro et al., 2018). This process leads to the decrease of
TrkB-FL levels and the generation of two distinct fragments:
a membrane-bound truncated receptor (TrkB-T′) and an
intracellular fragment (TrkB-ICD). In addition, we already
confirmed TrkB-FL cleavage and consequent TrkB-ICD
formation in the human brain (Jerónimo-Santos et al.,
2015).
In this work we characterized TrkB-ICD regarding its
stability, localization and molecular function in rat neuronal
cells and in a neuroglioma cell line. We found that TrkB-ICD
is a stable fragment, which, over time, translocates into
nucleus and phosphorylates nuclear and axonal proteins. Taken
together, these data strongly suggest that TrkB-FL cleavage
could be an important step of AD pathophysiology, since it
leads to a loss of BDNF signaling and furthermore forms an
intracellular fragment that might propagate Aβ toxicity to the
neurons.
MATERIALS AND METHODS
Materials and Methods are fully described in Supplementary
Material and in Supplementary Table S1.
RESULTS
TrkB-ICD Fragment: Determination of
Half-Life Time and Intracellular
Localization
TrkB-ICD stability in vitro was assessed by determining its
half-life time (T1/2). After 16 h of transfection with TrkB-ICD
vector, H4 cells were treated with cycloheximide (CHX, 5 µM),
an inhibitor of protein biosynthesis, for 8 h and 24 h.
TrkB-ICD levels were quantified at 0 h, 8 h and 24 h
after CHX treatment; a time-dependent gradual decrease of
TrkB-ICD expression levels was detected (Figures 1A,B). After
8 h of CHX exposure there was a significant decrease on
TrkB-ICD expression levels (p < 0.0001) towards near 50%
of the value at time 0 (Figure 1B), whereas at 24 h of
incubation with CHX only residual levels of TrkB-ICD were
detected (p < 0.0001; Figures 1A,B). Data obtained using
primary neurons follow a similar pattern (Supplementary
Figure S1A). Mathematical treatment (Belle et al., 2006) of
the data obtained in H4 cells (Figure 1C) gave a degradation
rate constant of k = 0.086 and an estimative of T1/2 of
approximately 8 h.
To assess TrkB-ICD subcellular localization we started
by an in silico approach and evaluated the presence of
nuclear localization sequence (NLS), which codifies the
nuclear import of proteins (Lange et al., 2007; Kosugi et al.,
2009). The analysis of TrkB-ICD sequence performed by
a NLS prediction algorithm (Figures 1D,E, cNLS Mapper
software) revealed the presence of two bipartite NLS. In this
algorithm, scores of 9/10 codify proteins exclusively present
in nucleus, whereas scores of 1/2 indicate proteins only
present in cytoplasm. In our case, both predicted sequences
are characteristic of proteins that could be localized either in
nucleus or in cytoplasm (scores of 5.5 and 6.5; Kosugi et al.,
2009).
In TrkB-ICD transfected primary neurons there was a
time-dependent progressive increase in the nuclear expression
TrkB-ICD. Actually, after 4 h and 8 h of transfection,
TrkB-ICD is dispersed on the cell, while for 16 h and 24 h
of transfection we observed a significant increase in the
proportion of cells with TrkB-ICD staining exclusively in nucleus
(41.7% and 73.8%, respectively; Figure 1F). Representative
immunofluorescence images for 4 h- and 24 h-transfected
cells are shown in Figure 1G. That TrkB-ICD is progressively
translocated to the nucleus could also be concluded by
using a subcellular fractionation protocol, which allows to
distinguish three fractions: N, enriched in nuclear proteins;
cytosolic and membrane (C&M), enriched in cytoplasmic
and membrane proteins; H, total homogenate. Figure 1H
shows data from 24 h-transfected neurons, revealing that
TrkB-ICD is present with stronger intensity in the N fraction
than in the C&M fraction. TrkB-ICD nuclear translocation
was also detected in H4 cells, however with a different
temporal pattern, since the presence in the nucleus was
only detected after 48 h of transfection (Supplementary
Figure S1B).
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FIGURE 1 | Determination of Intracellular Domain of Tropomyosin-receptor kinase B (TrkB-ICD) half-life time and its subcellular localization overtime using in vitro
and in silico approaches. (A) Representative western-blot probed with anti-Trk C-terminal antibody (C-14) for H4 cells 16 h-transfected with pcDNA-TrkB-ICD
plasmid (ICD) or EV plasmid incubated with CHX for different periods of time: 8 and 24 h. CTR corresponds to cells non-transfected. (B) Analysis of bands intensities
represented in (A) from densitometry quantification of TrkB-ICD immunoreactivity of three independent cultures. Data is normalized to the amount of TrkB-ICD
fragment detected on cells non-treated with CHX (CHX 0 h). GAPDH was used as loading control. Data is represented as mean ± SEM (∗∗∗∗p < 0.001; CHX 8 h and
CHX 24 h compared to “CHX 0h”; one-way ANOVA followed by Bonferroni post-test; F = 323.7). (C) Ln-transformation of TrkB-ICD levels. The slope of the linear
regression presented on the top (k = 0.086) corresponds to the decay rate constant. (D) Results obtained from cNLS Mapper software about prediction of NLS on
TrkB-ICD sequence. Red color identifies bipartite NLS. (E) Presentation of the initial amino acid position, sequence and respective score associated to each
predicted NLS. (F) Quantification of TrkB-ICD staining distribution overtime in TrkB-ICD-positive cells (representatively shown in G). Yellow color identifies cells that
present TrkB-ICD staining dispersed over the cell, while blue color represents cells where TrkB-ICD expression was exclusively detected in cell nuclei. Sample size for
each transfection time: 4 h, n = 12 TrkB-ICD-positive cells; 8 h, n = 33 TrkB-ICD-positive cells; 16 h, n = 12 TrkB-ICD-positive cells; 24 h, 237 TrkB-ICD-positive
cells. (G) Immunofluorescence image of 7 DIV primary neuronal cultures transfected with pcDNA-TrkB-ICD plasmid for 4 h (upper line) and 24 h (lower line).
Representative image of primary neurons depicting TrkB-ICD [green, stained with anti-Trk C-terminal antibody (C-14)] and neuronal marker Map2 (red, stained with
anti-Map2 antibody). Last image shows all channels merged with cell nuclei staining in blue (DAPI staining). Widefield fluorescence images were acquired with a 40×
objective (upper line, scale bar 50 µm) and 63x objective (lower line, scale bar 25 µm). (H) Western-blot image of homogenate (H), cytosolic and membrane (C&M)
and nuclear (N) fractions of 7 DIV primary neuronal cultures transfected for 24 h with pcDNA-TrkB-ICD and EV plasmid, showing the levels of GAPDH (cytosolic
marker), Lamin B (nuclear marker) and TrkB-ICD. Abbreviations: CHX, cycloheximide; CTR, control; C&M, fraction enriched in cytoplasmic and membrane; EV, empty
vector; H, Homogenate; ICD, intracellular domain; N, fraction enriched in nuclear proteins; NLS, Nuclear Localization Sequence; Pos., Position.
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TrkB-ICD Fragment: Characterization of
Tyrosine Kinase Activity and Its Influence
Upon Nuclear Translocation
Considering that TrkB-ICD contains a TrkB-FL tyrosine kinase
domain and also that phosphorylation is a central step for
many biologic processes, we evaluated whether this fragment
could per se present kinase activity. To do so, we used
an antibody (PY99) that specifically detects phosphotyrosine-
containing proteins and evaluated, through western-blotting and
immunofluorescence assays, phosphotyrosine immunoreactivity
of 24 h-transfected primary neurons. As shown in Figure 2B,
expression of TrkB-ICD induced a massive phosphorylation
pattern of several proteins. Similar results were found in H4 cells
transfected cells (Supplementary Figure S1C). Importantly, only
cells expressing TrkB-ICD show staining for phosphorylated
proteins at tyrosine residues. Moreover our data reveals
that during the 24 h transfection period, TrkB-ICD could
induce phosphorylation of somatic, nuclear and axonal proteins
(Figures 2A1,A2).
We then evaluated if TrkB-ICD nuclear translocation was
dependent on its kinase activity. To do so, immunofluorescence
assays were performed using 24 h-transfected primary neurons
incubated with K252a (200 nM), which inhibits Trk-FL
kinase activity (Ohmichi et al., 1992). Under these conditions,
TrkB-ICD immunolabeling was dispersed throughout all cell
body and axons (Figure 2D). Accordingly, there was a marked
decrease in the percentage of cells with staining exclusively
on the nucleus (from 73.8% to 14.8%, Figure 2C) and
marked increases TrkB-ICD detection in the cytoplasmic and
membrane fraction (Figure 2E). These data strongly suggest
that kinase activity is a requisite for nuclear translocation of the
TrkB-ICD.
To further characterize TrkB-ICD kinase activity, we
evaluated the mechanisms underlying the phosphorylation
profile. Accordingly, 24 h-transfected primary neurons were
incubated with inhibitors of crucial signaling pathways. For
that, we measured the ratio between levels of phosphorylated
proteins and TrkB-ICD levels, to cancel out any influence of these
drugs on the transfection/expression of TrkB-ICD levels. Indeed,
some drugs affected TrkB-ICD levels (Figure 2F), possibly
by influencing either its production and/or its degradation.
Importantly, however, the ratio between the total amounts of
phosphorylated proteins over the amounts of Trk-B-ICD was
markedly decreased by inhibitors of protein kinase A (PKA) and
PKC (H-89 and Staurosporine, STS inhibitors, respectively), an
effect with a similar magnitude to K252a effect (p-value = 0.0292,
p-value = 0.0039 and p-value = 0.0045, respectively, when
compared to non-treated TrkB-ICD-transfected cells). These
data indicate that PKA and PKC belong to the signaling cascade
operated by TrkB-ICD that lead to protein phosphorylation
(Figure 2G).
Finally, to further assess the role of TrkB-ICD as a trigger
to the phosphorylation, we evaluated whether inhibition of its
kinase activity as well as inhibition of its de novo synthesis, would
affect overall phosphorylation. When 16 h-transfected primary
neurons were incubated with K252a (200 nM) for 2 h, 8 h and
24 h, the overall levels of protein phosphorylation markedly
decreased, being already nearly absent after 2 h of incubation
with the tyrosine kinase inhibitor (Figure 2H). This indicates that
phosphorylated proteins are quickly de-phosphorylated in the
absence of TrkB-ICD activity. When 16 h-transfected primary
neurons treated with CHX for the different periods, there was
a progressive decline of the levels of phosphorylated proteins
(Figure 2I), which is accompanied by a progressive decline of
TrkB-ICD itself, thus reinforcing the conclusion that TrkB-ICD
is a trigger for protein phosphorylation.
DISCUSSION
The present work demonstrates, for the first time, that TrkB-
ICD: (I) is a relatively stable protein; (II) phosphorylates several
proteins; and (III) accumulates in the nucleus (Figure 3).
Previously, we described that TrkB-FL could be cleaved by
Aβ peptide accumulation (Jerónimo-Santos et al., 2015). This
cleavage has been demonstrated in several excitotoxic conditions
(Gomes et al., 2012; Vidaurre et al., 2012; Danelon et al.,
2016) and may have a major impact in long-lasting excitotoxic
conditions, such as Aβ peptide accumulation in AD.
It is widely known that BDNF and TrkB-FL constitute a major
signaling pathway in the developing and adult mammalian brain,
being implicated in neuronal differentiation, growth, survival
and plasticity (Lewin and Barde, 1996; Huang and Reichardt,
2001). Therefore, the appropriate function of this signaling
pathway is crucial for the central nervous system homeostasis,
and its dysregulation might lead to neuronal damage. It is
already known that an impaired BDNF/TrkB-FL system plays
an important role in the pathogenesis of AD (Phillips et al.,
1991; Connor et al., 1997; Ferrer et al., 1999; Arancibia et al.,
2008; Zuccato and Cattaneo, 2009; Kemppainen et al., 2012;
Nagahara et al., 2013; Jerónimo-Santos et al., 2015). Existing
data demonstrate that pro-BDNF, BDNF and TrkB-FL levels
are reduced in the brain of AD patients, while TrkB-Tc are
increased (Connor et al., 1997; Ferrer et al., 1999; Michalski and
Fahnestock, 2003). Importantly, the overexpression of TrkB-FL
in the AD APP/PS1 mouse model, reduces memory impairment
(Kemppainen et al., 2012). Though attention has been focused
in the loss of function of TrkB-FL, knowledge of the action
of the intracellular fragment is crucial for a full understanding
of the mechanisms underlying AD pathophysiology and thus,
for the design of strategies to mitigate its progression. This
is particularly important if one considers the high stability
of TrkB-ICD when compared to other intracellular fragments.
For instance, the p25 fragment is only detected for around
3 h after an insult (Patrick et al., 1999). Being a more stable
protein fragment, TrkB-ICD can probably have larger effects
on cellular processes. Its translocation and accumulation in the
cell nucleus, further suggests a persistent effect of TrkB-ICD on
cellular homeostasis. In addition, it is also known that AD is
characterized by a dysregulation in phosphatase activity, leading
to an overall increase in kinase activity (Kuban-Jankowska
et al., 2015). Given the spontaneous kinase activity of TrkB-ICD
fragment, we can hypothesize that this fragment could also
influence the kinase/phosphatase balance, leading to increased
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FIGURE 2 | Molecular characterization of TrkB-ICD tyrosine kinase activity. (A) Immunofluorescence images of 7 DIV primary neuronal cultures transfected with
pcDNA-TrkB-ICD plasmid for 24 h. Each line shows images with different staining in green channel: (A1) line—TrkB-ICD [stained with anti-Trk C-terminal tail antibody
(C-14); (A2) line—Tau (stained with anti-Tau antibody)]. Red color identifies phosphorylated proteins in tyrosine residues (stained with anti-PY99 antibody). Last image
shows all channels merged, including cell nuclei staining in blue (DAPI staining). Widefield fluorescence images were acquired with a 40× (scale bar 50 µm).
(B) Representative western-blot images of tyrosine phosphorylated proteins (stained with PY99 antibody) on 7 DIV primary neuronal cultures transfected for 24 h with
TrkB-ICD (ICD) and EV. CTR corresponds to non-transfected cells. (C) Quantification of TrkB-ICD staining distribution in TrkB-ICD-positive cells incubated (“+ K252a,”
n = 27 TrkB-ICD-positive cells) or not (−K252a,” n = 237 TrkB-ICD-positive cells) with K252a compound, which inhibits tyrosine kinase activity (representative image
shown in D). Yellow color identifies cells that present TrkB-ICD staining dispersed over the cell, while blue color represents cells where TrkB-ICD expression
(Continued)
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FIGURE 2 | Continued
was exclusively detected in cell nuclei. (D) Immunofluorescence images of
7 DIV primary neuronal cultures transfected with pcDNA-TrkB-ICD plasmid for
24 h: non-treated with K252a (upper line) and treated with K252a for 24 h
(lower line). In both conditions, green stains TrkB-ICD [stained with anti-Trk
C-terminal tail antibody (C-14)] and red stains phosphorylated proteins
(stained with anti-PY99 antibody). Last image shows all channels merged,
including cell nuclei staining in blue (DAPI staining). Widefield fluorescence
images were acquired with a 40x objective (scale bar: 50 µm).
(E) Western-blot image of homogenate (H), C&M and nuclear (N) fractions of
7 DIV primary neuronal cultures transfected for 24 h with pcDNA-TrkB-ICD
plasmid and simultaneously treated or not with K252a compound, showing
the levels of GAPDH (cytosolic marker), Lamin B (nuclear marker) and
TrkB-ICD. (F) Representative western-blot probed with anti-Trk C-terminal tail
antibody (C-14) and anti-PY99 antibody for 7 DIV primary neuronal cultures
transfected with pcDNA-TrkB-ICD plasmid incubated with several inhibitors
for 24 h. Each drug was selectively used to inhibit pathways involved in
TrkB-FL cascade signaling (PP2 10 µM, Src; LY294022 10 µM, Akt; U73122
4 µM, PLCγ; U0126 10 µM, Erk; H-89 25 µM, PKA; staurosporine, STS,
100 µM, PKC). (G) Ratio of quantification of phosphorylated proteins
immunoreactivity and quantification of TrkB-ICD immunoreactivity of eight
independent cultures. Data is normalized for cells transfected without
treatment and represented as mean ± SEM (p-value = 0.0292, H-89
treatment compared to cells non-treated; p-value = 0.0039, STS treatment
compared to cells non-treated; p-value = 0.0045, K252a treatment
compared to cells non-treated; ANOVA followed by Bonferroni post-test;
F = 6.63). (H) Representative western-blot probed with anti-Trk C-terminal tail
antibody (C-14) and anti-PY99 antibody for 7 DIV primary neuronal cultures
transfected with pcDNA-TrkB-ICD plasmid incubated with K252a (200 nM) for
different periods of time: 2, 8 and 24 h. (I) Representative western-blot
probed with anti-Trk C-terminal tail antibody (C-14) and anti-PY99 antibody
for 7 DIV primary neuronal cultures transfected with pcDNA-TrkB-ICD plasmid
for 16 h that were then incubated with CHX for different periods of time: 4,
8 and 24 h. Abbreviations: CHX, cycloheximide; CTR, non-transfected cells;
C&M, fraction enriched in cytoplasmic and membrane; EV, empty vector;
H, Homogenate; ICD, intracellular domain; N, fraction enriched in nuclear
proteins; NLS, Nuclear Localization Sequence; Pos, Position;
STS, staurosporine; ns, non significant.
levels of phosphorylated proteins, such as Tau. Nevertheless, it is
important to acknowledge that we observed a slight difference in
the phosphorylation levels, detected by PY99 antibody, between
control and transfection with the empty vector (EV). This
difference could be attributed to the transfection process, but
does not alter the main finding herein described: the strong
tyrosine-phosphorylation mediated by TrkB-ICD fragment. On
the other hand, despite the evidence that the expression of
TrkB-ICD induces a robust protein phosphorylation, it is
not clear whether it does so, by directly phosphorylating
target proteins, or by an indirect mechanism, inducing the
phosphorylation of intermediate proteins. The Ser/Thr kinase
family may also be one of these intermediate proteins, since their
inhibition affects overall protein phosphorylation, suggesting
that TrkB-ICD may have additional targets than Tyrosine
residues alone. Additionally, TrkB-ICD could be also affecting
gene expression in the nucleus, similar to the fragment formed
from β-catenin cleavage (Abe and Takeichi, 2007).
Our data also demonstrate that TrkB-ICD translocation
to the cell nucleus is dependent on tyrosine kinase activity.
This is in accordance with previous findings that NLS
can be upregulated by phosphorylation, facilitating nuclear
translocation of several proteins, namely enzymes devoted to
mediate nuclear translocation processes, such as importins
(Nardozzi et al., 2010).
Our data show that this protein phosphorylation mediated by
TrkB-ICD is not restricted to the nucleus. It can affect different
cell compartments and may require the activity of kinases other
than tyrosine kinases, namely PKA as assessed by using H-89,
a PKA inhibitor. Data obtained with staurosporine may suggest
involvement of PKC, but since staurosporine may also inhibit
tyrosine kinase activity (Ohmichi et al., 1992), this should be
taken into account.
Given that TrkB-ICD possesses the kinase domain of TrkB-FL
receptor, it could directly activate the canonical pathways
triggered by TrkB-FL (PLCγ, PI3K/AKT and MAPK pathways),
having therefore a protective role. Although we do not exclude
that hypothesis, it is unlikely that TrkB-ICD could have this
putative protective role, since TrkB-ICD only has the anchorage
site for PLCγ and we do not detect (results not shown) any
activation of the three pathways. Furthermore, these mediators
of TrkB-FL signaling are in close vicinity to the cytoplasmic
membrane and our data suggest that TrkB-ICD is mainly located
on nucleus.
Calpain-mediated cleavage of several proteins, namely of
p35, β-catenin or mGluR1α proteins, leads to the formation
of intracellular fragments known to be involved in neuronal
death, hyperphosphorylation of Tau protein, excitotoxicity,
gene transcription modifications (Patrick et al., 1999; Abe
and Takeichi, 2007; Xu et al., 2007). The present work by
showing that TrkB-ICD is stable and affects the degree of
phosphorylation of several proteins, (cytoplasmic, axonal and
nuclear), highlights a novel mechanism through which Aβ-
peptide could induce neuronal damage. Besides the loss of
neuroprotection due to TrkB-FL cleavage, a gain of toxic
function might occur due to the formation of a stable
fragment with high phosphorylating potential, the TrkB-
ICD.
Since this overexpression of TrkB-ICD is mechanistically
different from the TrkB-ICD released from Aβ-induced TrkB-FL
cleavage, one should acknowledge that the findings herein
described could be different from those triggered by the
TrkB-ICD in vivo. On spite of the different origins of TrkB-ICD
in those conditions, the TrkB-ICD sequence is exactly the
same. In addition, the transfection method, even with intrinsic
limitations, allows the evaluation of TrkB-ICD impact on cell
environment per se without any other effect that could be
attributed to Aβ peptide and/or calpain activation.
Current therapies for AD only alleviate symptoms and
do not target the etiology itself. Our data highlights a new
diagnostic and/or therapeutic target against AD by showing that
the TrkB-ICD fragment might play an important role in the
Aβ toxicity cascade. This constitutes a step forward towards
the clarification of the molecular mechanisms underlying AD
pathophysiology.
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FIGURE 3 | BDNF and its functional receptor TrkB-FL constitute one of the major pathways responsible for endogenous neuroprotection. Actually, after recognition
of homodimeric BDNF, TrkB-FL receptor dimerizes and transactivates its tyrosine kinase domain, triggering three different signalling pathways (MAPK/Erk, PI3K/Akt
and PLCγ), which promote neuronal growth, survival, differentiation and plasticity and regulate learning and memory processes. This system is, therefore, really
crucial to the homeostasis maintenance of the mammalian nervous system (Huang and Reichardt, 2001). However in Alzheimer’s disease it is already known that Aβ
peptide could lead to an increase on intracellular Ca2+ mediated by overactivation of extrasynaptic NMDA receptors (NMDAr) (Tanqueiro et al., 2018). This increase
in Ca2+ levels will then promote a sustained activation of calpains, which will cleave TrkB-FL and forms two different fragments: a membrane-bound fragment,
TrkB-T′, and an intracellular fragment, TrkB-ICD (Jerónimo-Santos et al., 2015). In this work, using different techniques and samples from a neuroglioma cell line and
primary neuronal cultures, we clearly showed that TrkB-ICD is a stable fragment, which is translocated to cell nucleus after its formation and also that phosphorylates
axonal, somal and nuclear proteins.
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